LVTX — LAVA Therapeutics NV Share News
0.000.00%
Last trade - 00:00- $45.77m
- -$3.89m
- $11.98m
U.S. STOCKS ON THE MOVE-Digital World Acquisition, Carnival, Crypto stocks
U.S. STOCKS ON THE MOVE-Arcutis Biotherapeutics, Chegg, Li Auto
Brief: Seagen And Lava Therapeutics Announce Exclusive Worldwide License Agreement To Advance Lava-1223, A Preclinical Gamma Delta Bispecific T Cell Engager For EGFR-Expressing Solid Tumors
Lava Therapeutics more than doubles after giving cancer drug license to Seagen
Brief: Lava Therapeutics Posts Cash And Investments Of $110.7 Mln As Of June 30
Lava Therapeutics Nv Reports Results For The Quarter Ended In June: Earnings Summary
Lava Therapeutics Nv Expected To Post A Loss Of 59 Cents A Share: Earnings Preview
Brief: Lava Therapeutics Highlights Encouraging Clinical Updates On Lead Program, Lava-051, In Chronic Lymphocytic Leukemia And Multiple Myeloma Patients
Brief: Lava Therapeutics Announces Two Appointments To Board Of Directors
Brief: LAVA Therapeutics to Present Initial Data of LAVA-051 in Chronic Lymphocytic Leukemia and Multiple Myeloma at 2022 ASCO Annual Meeting
Lava Therapeutics Nv Reports Results For The Quarter Ended In March: Earnings Summary
Brief: Lava Therapeutics Provides Business Update And Reports First Quarter Financial Results
Lava Therapeutics Nv Expected To Post A Loss Of 81 Cents A Share: Earnings Preview
Lava Therapeutics gains as U.S. FDA allows lead drug clinical trial
Brief: Lava Therapeutics Announces FDA IND Clearance For Lava-051 For Treatment Of Hematologic Malignancies
Brief: Lava Therapeutics To Present Updated Lava-051 Clinical Data At Meeting
U.S. RESEARCH ROUNDUP- Airbnb, Exelon, Netflix
Brief: Lava Therapeutics Files For Mixed Shelf Of Up To $250 Mln
Brief: Lava Therapeutics Provides Business Update And Reports Q4 And Year End 2021 Financial Results